共 50 条
- [1] Tretinoin enhances the efficacy of combined BRAF, MEK, and EGFR inhibition in BRAFV600E colorectal cancer cellsCANCER SCIENCE, 2024, 115 : 600 - 600Yoshida, YuyaTakahashi, MasanobuNumakura, RyunosukeTaniguchi, SaukuraKomine, KeigoIshioka, Chikashi
- [2] Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)Higgins, BrianKolinsky, Kenneth DanielYang, HongKim, Min JungLi, Jia KuiGo, ZenaidaPackman, KathrynBollag, GideonSu, Fei
- [3] The combination of ulixertinib(ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical modelsCANCER RESEARCH, 2023, 83 (07)Knoerzer, DeborahReddy, AnupamaBox, Jessica A.Groover, AnnaKreider, BrentTeresk, MartinEmery, Caroline M.
- [4] ERK1/2 inhibitor ulixertinib demonstrates activity in atypical (non-V600) BRAF mutant modelsCANCER RESEARCH, 2022, 82 (12)Knoerzer, DeborahReddy, AnupamaDerti, AdnanEmery, Caroline M.
- [5] Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer modelsCANCER RESEARCH, 2012, 72Yang, HongHiggins, BrianKolinsky, KennethLi, JiakuiMargolis, RichardGo, ZenaidaRailkar, ArunaPackman, KathrynBollag, GideonSu, Fei
- [6] Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patientsANNALS OF ONCOLOGY, 2020, 31 : S226 - S227Corcoran, R.Giannakis, M.Allen, J.Chen, J.Pelka, K.Chao, S.Meyerhardt, J.Enzinger, A.Enzinger, P.McCleary, N.Yugelun, M.Abrams, T.Kanter, K.Van Seventer, E.Bradford, W.Fetter, I.Siravegna, G.Tian, J.Clark, J.Ryan, D.Hacohen, N.Parikh, A.
- [7] Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAFV600E colorectal cancerCANCER SCIENCE, 2024, 115 (11) : 3740 - 3754Yoshida, YuyaTakahashi, MasanobuTaniguchi, SakuraNumakura, RyunosukeKomine, KeigoIshioka, Chikashi
- [8] Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trialNature Medicine, 2023, 29 : 458 - 466Jun TianJonathan H. ChenSherry X. ChaoKarin PelkaMarios GiannakisJulian HessKelly BurkeVjola JorgjiPrincy SindurakarJonathan BravermanArnav MehtaTomonori OkaMei HuangDavid LiebMaxwell SpurrellJill N. AllenThomas A. AbramsJeffrey W. ClarkAndrea C. EnzingerPeter C. EnzingerSamuel J. KlempnerNadine J. McClearyJeffrey A. MeyerhardtDavid P. RyanMatthew B. YurgelunKatie KanterEmily E. Van SeventerIslam BaievGary ChiJoy JarnaginWilliam B. BradfordEdmond WongAlexa G. MichelIsobel J. FetterGiulia SiravegnaAngelo J. GemmaArlene SharpeShadmehr DemehriRebecca LearyCatarina D. CampbellOmer YilmazGad A. GetzAparna R. ParikhNir HacohenRyan B. Corcoran
- [9] Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trialNATURE MEDICINE, 2023, 29 (02) : 458 - +Tian, JunChen, Jonathan H. H.Chao, Sherry X. X.Pelka, KarinGiannakis, MariosHess, JulianBurke, KellyJorgji, VjolaSindurakar, PrincyBraverman, JonathanMehta, ArnavOka, TomonoriHuang, MeiLieb, DavidSpurrell, MaxwellAllen, Jill N. N.Abrams, Thomas A. A.Clark, Jeffrey W. W.Enzinger, Andrea C. C.Enzinger, Peter C. C.Klempner, Samuel J. J.McCleary, Nadine J. J.Meyerhardt, Jeffrey A. A.Ryan, David P. P.Yurgelun, Matthew B. B.Kanter, KatieVan Seventer, Emily E. E.Baiev, IslamChi, GaryJarnagin, JoyBradford, William B. B.Wong, EdmondMichel, Alexa G. G.Fetter, Isobel J. J.Siravegna, GiuliaGemma, Angelo J. J.Sharpe, ArleneDemehri, ShadmehrLeary, RebeccaCampbell, Catarina D. D.Yilmaz, OmerGetz, Gad A. A.Parikh, Aparna R. R.Hacohen, NirCorcoran, Ryan B. B.
- [10] Preclinical validation of ERK inhibition via GDC-0994 as a potent therapeutic strategy in BRAFV600E mutant colorectal cancersEUROPEAN JOURNAL OF CANCER, 2016, 69 : S30 - S30Schaefer, G.Chan, J.Shao, L.Kirouac, D.Orr, C.Hunsaker, T.De la Cruz, C.Merchant, M.